Haemonetics (NYSE:HAE) reported Q4 EPS of $0.65, $0.06 better than the analyst estimate of $0.59. Revenue for the quarter came in at $265 million versus the consensus estimate of $257.82 million.
GUIDANCE:
Haemonetics sees FY2023 EPS of $2.50-$2.90, versus the consensus of $2.53.